Terms: = Lymphoma AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
94 results:
1. [Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell lymphoma Cells].
Zhang YL; Chen YH; Zheng RJ; Zheng KJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):470-475. PubMed ID: 38660854
[TBL] [Abstract] [Full Text] [Related]
2. xpo1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract] [Full Text] [Related]
3. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract] [Full Text] [Related]
4. xpo1-Mediated mRNA Export of Genome Maintenance Regulators Drives Chemotherapy Resistance in Aggressive lymphoma.
Knittel G; Reinhardt HC
Cancer Res; 2024 Jan; 84(1):3-5. PubMed ID: 37902414
[TBL] [Abstract] [Full Text] [Related]
5. The synergy of the xpo1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.
Deng M; Tan J; Fan Z; Pham LV; Zhu F; Fang X; Zhao H; Young K; Xu B
Sci Rep; 2023 Oct; 13(1):18554. PubMed ID: 37899423
[TBL] [Abstract] [Full Text] [Related]
6. Discovery and biological evaluation of a potent small molecule crm1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma.
Liu H; Liu M; Tian X; Wang H; Gao J; Li H; Zhao Z; Liu Y; Liu C; Chen X; Yang Y
Elife; 2023 Oct; 12():. PubMed ID: 37888961
[TBL] [Abstract] [Full Text] [Related]
7. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
Yuan S; Zuo W; Liu T; Fu H
Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
[No Abstract] [Full Text] [Related]
8. xpo1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Marullo R; Rutherford SC; Revuelta MV; Zamponi N; Culjkovic-Kraljacic B; Kotlov N; Di Siervi N; Lara-Garcia J; Allan JN; Ruan J; Furman RR; Chen Z; Shore TB; Phillips AA; Mayer S; Hsu J; van Besien K; Leonard JP; Borden KLB; Inghirami G; Martin P; Cerchietti L
Cancer Res; 2024 Jan; 84(1):101-117. PubMed ID: 37801604
[TBL] [Abstract] [Full Text] [Related]
9. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract] [Full Text] [Related]
10. xpo1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Fisher JG; Doyle ADP; Graham LV; Sonar S; Sale B; Henderson I; Del Rio L; Johnson PWM; Landesman Y; Cragg MS; Forconi F; Walker CJ; Khakoo SI; Blunt MD
Leukemia; 2023 Oct; 37(10):2036-2049. PubMed ID: 37528310
[TBL] [Abstract] [Full Text] [Related]
11. USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing xpo1.
Zhang Y; Lu P; Jin S; Zhang J; Zhou Y
Int J Med Sci; 2023; 20(5):616-626. PubMed ID: 37082728
[No Abstract] [Full Text] [Related]
12. Direct interaction between mortalin and HIF-1α at the mitochondria inhibits apoptosis by blocking recruitment of Bax.
Yfantis A; Mylonis I; Simos G
FEBS J; 2023 Aug; 290(15):3764-3780. PubMed ID: 36825991
[TBL] [Abstract] [Full Text] [Related]
13. [The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin lymphoma --Review].
Tang XY; Wang Y; Xu RR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):292-296. PubMed ID: 36765514
[TBL] [Abstract] [Full Text] [Related]
14. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of xpo1.
Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
[TBL] [Abstract] [Full Text] [Related]
15. Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma.
Caillot M; Miloudi H; Taly A; Profitós-Pelejà N; Santos JC; Ribeiro ML; Maitre E; Saule S; Roué G; Jardin F; Sola B
Mol Oncol; 2023 Dec; 17(12):2546-2564. PubMed ID: 36727672
[TBL] [Abstract] [Full Text] [Related]
16. Protein biomarkers for response to xpo1 inhibition in haematologic malignancies.
Totiger TM; Chaudhry S; Musi E; Afaghani J; Montoya S; Owusu-Ansah F; Lee S; Schwartz G; Klimek V; Taylor J
J Cell Mol Med; 2023 Feb; 27(4):587-590. PubMed ID: 36722323
[TBL] [Abstract] [Full Text] [Related]
17. Nuclear Export in Non-Hodgkin lymphoma and Implications for Targeted xpo1 Inhibitors.
Trkulja KL; Manji F; Kuruvilla J; Laister RC
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671496
[TBL] [Abstract] [Full Text] [Related]
18. Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell lymphomas.
Singh K; Lezama LS; Kurzer J; Oak J; Schultz LM; Walkush A; Cheng TC; Chen EH; May WA; Chang C; Link MP; Advani RH; Suarez CJ; Natkunam Y
Am J Surg Pathol; 2023 Jan; 47(1):81-90. PubMed ID: 36001451
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic and therapeutic significance of xpo1 in T-cell lymphoma.
Nie D; Xiao X; Chen J; Xie S; Xiao J; Yang W; Liu H; Wang J; Ma L; Du Y; Huang K; Li Y
Exp Cell Res; 2022 Jul; 416(2):113180. PubMed ID: 35489384
[TBL] [Abstract] [Full Text] [Related]
20. Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.
Ishikawa C; Mori N
Invest New Drugs; 2022 Aug; 40(4):718-727. PubMed ID: 35477814
[TBL] [Abstract] [Full Text] [Related]
[Next]